Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
Pratteln, Switzerland, June 27, 2022 -- Santhera Pharmaceuticals (SIX: SANN) announces that Chairman of the Board Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting on June 30, 2022. The Board of Directors has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee.
Elmar Schnee, Chairman of the Board and member of the Compensation Committee of Santhera since 2017, will not stand for re-election and will step down from Santhera's Board of Directors as of June 30, 2022. The Board of Directors expresses its sincerest gratitude to Mr. Schnee for his valued leadership over the past, challenging years.
The Board of Directors of Santhera has unanimously nominated Thomas Meier, PhD, for election as Chairman of the Board and as member of the Compensation Committee. Thomas Meier, PhD, was CEO of Santhera from October 2011 to November 2019 and has been a director of the Company since 2017.
The Board of Directors seeks to nominate one or more additional members of the Board of Directors at a later stage.
The updated proposals of the Board of Directors to the Annual General Meeting of June 30, 2022 can be downloaded at https://www.santhera.com/share-bondholder-meetings. Shareholders eligible to vote may grant powers of attorney and give instructions to the independent proxy or change instructions that had been electronically given until June 28, 2022, 11.59 pm (CEST). Unless other instructions are given to the independent proxy, the independent proxy, in accordance with the proxy form or electronic instruction form, is appointed to vote for the proposals made by the Board of Directors, including the amendments announced today.
